A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study

The standard first line therapy for patients with multiple myeloma includes three phases: An initial induction therapy followed by consolidation with autologous hematopoietic cell transplantation (...

[1]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[2]  K. Anderson,et al.  Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond , 2017, Leukemia.

[3]  Sin-Ho Jung,et al.  Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Hari,et al.  Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014 , 2017, Leukemia.

[5]  C. Hofmeister,et al.  Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  M. Boccadoro,et al.  Autologous transplantation and maintenance therapy in multiple myeloma. , 2014, The New England journal of medicine.

[7]  S. Devlin,et al.  Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation , 2013, Bone Marrow Transplantation.

[8]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[9]  K. Owzar,et al.  Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[10]  M. Dimopoulos,et al.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. , 2011, Blood.

[11]  U. Mellqvist,et al.  Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. , 2006, Haematologica.

[12]  J. S. San Miguel,et al.  Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. , 2002, Haematologica.